Observational analysis shows methylphenidate modulates beta oscillations in cortico-striatal networks, influencing impulsive choice behavior.
Impulsive choice- preferring small, immediate rewards over larger, delayed reward- is a hallmark of many psychiatric disorders. Methylphenidate, a dopamine and noradrenaline transporter inhibitor, reduces impulsivity, but the neural mechanisms underlying this effect remain unclear. Identifying a neurophysiological signature of methylphenidate’s action could be used clinically to predict treatment response and guide drug development. To this end, we recorded local field potentials (LFP) from 32 electrodes spanning cortico-striatal circuits in rats performing a temporal discounting task, under saline or methylphenidate treatment conditions. Methylphenidate decreased beta frequency (15-30 Hz) power and connectivity for small, immediate rewards while simultaneously increasing beta power for large, delayed rewards. Reduced connectivity in cortico-striatal networks during small rewards predicted increased preference for delayed rewards. These findings suggest that methylphenidate influences discounting behavior by modulating reward-evoked beta oscillations in cortico-striatal networks. Thus, beta oscillations may serve as a translational biomarker of treatment responsivity to monoaminergic drugs, providing a circuit-level assay to measure and predict changes in impulsive behavior.
No takes yet. Share an insight, caveat, or question.
Nan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: